Secondary bacterial infections in patients with coronavirus disease 2019-associated pneumonia
AUTOR(ES)
Aydemir, Ozlem; Aydemir, Yusuf; Şahin, Elif Özözen; Şahin, Fatih; Koroglu, Mehmet; Erdem, Ali Fuat
FONTE
Revista da Associação Médica Brasileira
DATA DE PUBLICAÇÃO
2022
RESUMO
SUMMARY OBJECTIVE: The vast majority of patients who hospitalized with coronavirus disease 2019 are given empirical antibiotic therapy. However, information on the frequency, microorganism species, and resistance rates of secondary bacterial infections in coronavirus disease 2019 patients are insufficient. We aimed to show the frequency of secondary infections and resistance conditions in patients with coronavirus disease 2019 hospitalized in the intensive care unit. METHODS: The results of tracheal aspirate culture, blood culture, and urine culture obtained from coronavirus disease 2019 patients – at least 2 days after their admission to the intensive care unit – were examined microbiologically. RESULTS: A total of 514 patients hospitalized in intensive care unit were included in our study. Tracheal aspirate, blood, or urine cultures were collected from 369 patients (71.8%). Bacterial reproduction was detected in at least one sample in 171 (33.3%) of all patients. The rate of respiratory tract infection and/or bloodstream infection was found to be 21%. Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa in tracheal aspirate culture; Coagulase-negative staphylococci, K. pneumoniae, and A. baumannii in blood culture; and Escherichia coli, K. pneumoniae, and Enterococcus faecalis in urine culture were the most common microorganisms. A. baumannii was resistant to most antibiotics except colistin and P. aeruginosa strains were resistant to most antibiotics except amikacin, colistin, cefepime, and imipenem. In K. pneumoniae, the highest meropenem sensitivity (73%) was observed; there was a strong resistance to most of the remaining antibiotics. CONCLUSIONS: We think that our study can be useful in choosing empirical antibiotic therapy in the coronavirus disease 2019 pandemic and reducing the mortality that may occur with secondary infection.
Documentos Relacionados
- A new biomarker in severe pneumonia associated with coronavirus disease 2019: hypoalbuminemia. A prospective study
- Cardiovascular drugs and analysis of potential risk factors associated with mortality in severe coronavirus disease 2019 patients
- Hemoglobin value may be decreased in patients with severe coronavirus disease 2019
- Autonomic heart rate modulation in patients with coronavirus disease 2019 in mechanical ventilation
- Coronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?